Astegolimab met its primary endpoint in the Phase IIb ALIENTO trial with a 15.4% reduction in annualized exacerbation rate at 52 weeks, while the Phase III ARNASA study showed a 14.5% reduction and ...

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...

"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...

One global clinical trial testing astegolimab for moderate to severe COPD hit its main goal, but another did not, Genentech ...

Topline data were announced from two phase 3 trials evaluating astegolimab in patients with moderate to very severe COPD.

Astegolimab, an anti-ST2 monoclonal antibody designed to block signaling of IL-33 under development by Roche's (OTCQX:RHHBY) Genentech unit, failed to meet its primary endpoint in a phase 3 trial for ...

Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), ...

The astegolimab COPD clinical program includes the phase 2b ALIENTO (ClinicalTrials.gov Identifier: NCT05037929) and the phase 3 ARNASA (ClinicalTrials.gov Identifier: NCT05595642) trials.

With astegolimab, Roche is hoping to join the group of biologic medicines available for COPD that is driven by inflammation. Last year, Dupixent added COPD to its list of FDA-approved indications.

Although treatment was well tolerated, astegolimab did not effectively improve primary or secondary outcome measurements in atopic dermatitis, according to a study published in The Journal of ...

The paper, ‘Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial’ is published in the Lancet Respiratory Medicine. Ends Journal ...